Abstract
Most of prostate cancers diagnosed at localized disease were regarded as less aggressive malignancy because of their indolent course; nonetheless, metastatic prostate cancer is still lethal. The 5-year survival rate approaches 100% for patients within localized disease, but it declined to 28% for metastatic disease [1]. About 4% of prostate cancer present metastasis on initial diagnosis, and about one-third of localized prostate cancer patients experience disease progression [2, 3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: a review. Urol Oncol. 2017;35(4):125–34.
David N, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–38.
Norum J, Nieder C. Treatments for metastatic prostate cancer (mPC): a review of costing evidence. Pharmacoeconomics. 2017;35:1–14.
Faiena I, Singer EA, Pumill C, Kim IY. Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (review). Int J Oncol. 2014;45(6):2193–8.
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.
Eddy C, Guillaume P, Mohamed MD, Vaudoyer D. Management of peritoneal carcinomatosis from colorectal cancer. Cancer J. 2009;15(3):243–8.
Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ. 20-year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012;110(11):1709–13.
Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Elizabeth B, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 2011;76(3):710–4.
Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol. 2004;171:668–71.
Ristau BT, Cahn D, Uzzo RG, Chapin BF, Smaldone MC. The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. Future Oncol. 2016;12(5):687–99.
Kaplan RN, Rafii S, Lyden D. Preparing the “Soil”: the premetastatic niche rosandra. Cancer Res. 2010;66(23):11089–93.
Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001;358(7):277–86.
Joniau S, Spahn M, Briganti A, et al. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. Eur Urol. 2014;67(2):319–25.
Löppenberg B, Dalela D, Karabon P, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol. 2017;72(1):14–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Yuk, H.D., Kwak, C. (2018). Role of Radical Prostatectomy in the Management of Metastatic Prostate Cancer. In: Kim, C. (eds) Management of Advanced Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-6943-7_7
Download citation
DOI: https://doi.org/10.1007/978-981-10-6943-7_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-6942-0
Online ISBN: 978-981-10-6943-7
eBook Packages: MedicineMedicine (R0)